Amneal Pharmaceuticals Inc (FRA:2DT)
€ 7.7 0 (0%) Market Cap: 2.45 Bil Enterprise Value: 4.93 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 62/100

Amneal Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 06:30PM GMT
Release Date Price: €4.44 (+8.29%)
Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst

So good morning, everybody. I'm Christopher Schott from JPMorgan. And it's my pleasure to be introducing Amneal today. From the company, we have Chirag and Chintu Patel, Co-Founders and Co-CEOs. And with that, I'll turn it over to Chirag.

Chirag K. Patel
Amneal Pharmaceuticals, Inc. - Co-Founder, Co-CEO, President & Director

Thank you, Chris. And thank you, everyone, for joining us today. We are thrilled coming back to Amneal 18 months ago. And 18 months ago, we left and came back 5 months ago. So it's not a long time that we were away but very thrilled and excited to rebuild Amneal 2.0, just like how we built Amneal 1.0. So many exciting areas of growth that we have. Let me walk you through.

So this is what we have done, we're calling it the reinvigoration of Amneal, and we had tremendous momentum in 2019 towards the end, entering into 2020. So on a business evolution front, as you saw, we launched 2 key products, first to market. We launched almost 15

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot